β‐Cell signalling and insulin secretagogues: A path for improved diabetes therapy
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Insulin secretagogues including sulfonylureas, glinides and incretin‐related drugs such as dipeptidyl peptidase 4 (DPP‐4) inhibitors and glucagon‐like peptide‐1 receptor agonists are widely used for treatment of type 2 diabetes. In addition, glucokinase activators and G‐protein‐coupled receptor 40 (GPR40) agonists also have been developed, although the drugs are not clinically usable. These different drugs exert their effects on insulin secretion by different mechanisms. Recent advances in β‐cell signalling studies have not only deepened our understanding of insulin secretion but also revealed novel mechanisms of insulin secretagogues. Clarification of the signalling mechanisms of the insulin secretagogues will contribute to improved drug therapy for diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., et al. (2003) · Nature · doi:10.1038/nature01478 · Cited by 1,538 · cited 2×
“GPR40, a member of the GPCR family, was identified as a receptor for fatty acids in 2003.(59,60) GPR40 is expressed at high levels in pancreatic β-cells, and mediates amplification of insulin secretion by long chain fatty acids in a glucosedependent manner.”
BackgroundTriggering and amplifying pathways of regulation of insulin secretion by glucose.
Henquin, J. C. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1751 · Cited by 1,201 · cited 1×
“(GIIS) comprises 2 pathways: the triggering pathway and the metabolic amplifying pathway.(1) The former involves closure of the ATP-sensitive K channel (KATP channels) by increased ATP concentration due to glucose metabolism, which is followed by Ca influx through voltage-dependent Ca channels that leads to insulin gr…”
BackgroundcAMP-GEFII is a direct target of cAMP in regulated exocytosis
Ozaki, N., Shibasaki, T., Kashima, Y., Miki, T., Takahashi, K., Ueno, H., Sunaga, Y., Yano, H., Matsuura, Y., Iwanaga, T., et al. (2000) · Nature Cell Biology · doi:10.1038/35041046 · Cited by 481 · cited 7×
“In addition to the β-cell KATP channel, Epac2A (see below) also has been shown to be a target of sulfonylureas excepting gliclazide.15 Glinides do not activate Epac2A.15 Epac2A is activated by cAMP and is important for IIIS.16,17 Mutational analysis of Epac2A has shown that the amino acid residues Gly114, Ser116 and H…”
BackgroundInfluentialSelf-citationHøjberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Kang, G., Joseph, J. W., Chepurny, O. G., Monaco, M., Wheeler, M. B., Bos, J. L., Schwede, F., Genieser, H.-G., & Holz, G. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211682200 · Cited by 298 · cited 1×
“In this process, Epac2A is involved in RyRmediated Ca mobilization.(33,41) In addition, it has been suggested that activation of PLC-ε by Epac2A stimulates IP3 receptor-mediated Ca mobilization.”
BackgroundTissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.
Gribble, F. M., Tucker, S. J., Seino, S., & Ashcroft, F. M. (1998) · Diabetes · doi:10.2337/diabetes.47.9.1412 · Cited by 263
Self-citationStructure of a Pancreatic ATP-Sensitive Potassium Channel
Li, N., Wu, J.-X., Ding, D., Cheng, J., Gao, N., & Chen, L. (2017) · Cell · doi:10.1016/j.cell.2016.12.028 · Cited by 252
Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment
Marquard, J., Otter, S., Welters, A., Stirban, A., Fischer, A., Eglinger, J., Herebian, D., Kletke, O., Klemen, M. S., Stožer, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3822 · Cited by 161 · cited 7×
“secretion through N-methyl-D-aspartic acid (NMDA) receptors and that NMDA receptor inhibition enhanced GIIS and improved glucose tolerance in a mouse model of T2D.(50)”
BackgroundInfluential
Cited by
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2019) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.07.017 · Cited by 156
Deshmukh, A., Chang, K., Cuala, J., Hernandez Campos, M. J., Mahmood, S., Verma, R., Georgia, S., Loconte, V., & White, K. L. (2025) · Structure · doi:10.1016/j.str.2025.07.022 · Cited by 9
Metadata
- Authors
- Seino, S., Sugawara, K., Yokoi, N., & Takahashi, H.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-09
- Volume
- 19
- Issue
- S1
- Pages
- 22-29
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2751070681
- Cited by
- 79
- References
- 16
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: β‐Cell signalling and insulin secretagogues: A path for improved diabetes therapy. https://app.cochat.ai/papers/10.1111/dom.12995
- The paper
- Seino, S., Sugawara, K., Yokoi, N., & Takahashi, H. (2017). β‐Cell signalling and insulin secretagogues: A path for improved diabetes therapy. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12995
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.